On January 9, 2024, Concord Healthcare Group Co., Ltd. (Concord Healthcare) successfully listed on the Main Board of the Stock Exchange of Hong Kong (SEHK), raising approximately HK$562.9 million (US$72.2 million) from its IPO. Wilson Sonsini Goodrich & Rosati acted as Concord Healthcare’s U.S. and Hong Kong counsel in the IPO and SEHK listing.

Concord Healthcare is an oncology healthcare service provider in China. The company provides a full spectrum of oncology healthcare services to cancer patients in its self-owned medical institutions and serves a widespread network of enterprise customers, primarily hospitals, with integrated oncology-related services through its medical equipment, software, and related services.

The Wilson Sonsini team that represented Concord Healthcare in the IPO and SEHK listing includes:

Corporate
Dan Ouyang
Winfield Lau
Can Yin
Ke Li
Xinyi Wang
Yu Ma
Ziyue Zhu
Giselle Ma
Olive Ma
Kelvin Lam

Tax
Myra A. Sutanto Shen
Nika Antonikova

For more information, please see the press release.